24 June 2016
By Dr Wendy Winnall - PCFA Research Team
Abiraterone (Zytiga) has given hope to men with the most feared form of prostate cancer, metastatic castration-resistant prostate cancer (mCPRC). A new study published in the journal Nature has shown that once Abiraterone enters the body, it is modified into different forms, some of which are very helpful in fighting the tumour, but some of which are not. The challenge is to modify Abiraterone therapy so it lives up to its full potential.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
